STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

|  |  |  |
| --- | --- | --- |
|  | Item No | Recommendation |
| **Title and abstract** | 1 | (*a*) Indicate the study’s design with a commonly used term in the title or the abstract. |
| (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found**We have included this information in the abstract** |
| Introduction |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported**We have explained the scientific background in the introduction** |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses**We have specified our objectives** |
| Methods |
| Study design | 4 | Present key elements of study design early in the paper**We have explained our study design in the methods section** |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection**We have described setting and relevant dates** |
| Participants | 6 | Give the eligibility criteria, and the sources and methods of selection of participants**We have described the eligibility criteria and the methods of selection** |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable**We have described all the factors risk, exposures and outcomes in the methods section. We have described all the used techniques** |
| Data sources/ measurement | 8\* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group**We have included and compared the different diagnostic procedures** |
| Bias | 9 | Describe any efforts to address potential sources of bias**We have described our potential limitations and our methodology in order to avoid bias** |
| Study size | 10 | Explain how the study size was arrived at**We have explained our methodology to calculate the study size** |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why**We have explained our methodology about quantitative variables** |
| Statistical methods | 12 | (*a*) Describe all statistical methods, including those used to control for confounding |
| (*b*) Describe any methods used to examine subgroups and interactions |
| (*c*) Explain how missing data were addressed |
| (*d*) If applicable, describe analytical methods taking account of sampling strategy |
| (*e*) Describe any sensitivity analyses**We have explained this information about statistical methods** |
| Results |
| Participants | 13\* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed |
| (b) Give reasons for non-participation at each stage |
| (c) Consider use of a flow diagram**We have included information about participants** |
| Descriptive data | 14\* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders |
| (b) Indicate number of participants with missing data for each variable of interest**We have explained characteristics of study participants** |
| Outcome data | 15\* | Report numbers of outcome events or summary measures**We have explained all possible outcomes and different ways of diagnosis and we have compared them** |
| Main results | 16 | (*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included |
| (*b*) Report category boundaries when continuous variables were categorized |
| (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period**We have explained all our main results in terms of risk and precision, we have reported category boundaries of continuous variables** |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses**We have made sensitivity, specificity and predictive values measures to compare different diagnostic tests** |
| Discussion |
| Key results | 18 | Summarise key results with reference to study objectives |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results**We have summarized key results, discussed our main limitations and considered interpretation of our findings** |
| Other information |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based**We have discussed about our funding** |

\*Give information separately for exposed and unexposed groups.